Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining MomentumInvestors Business Daily • 10/30/24
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains tractionCNBC • 10/30/24
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological DiseasesGlobeNewsWire • 10/29/24
Seeking Clues to Biogen (BIIB) Q3 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 10/28/24
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024GlobeNewsWire • 10/27/24
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual ConferenceGlobeNewsWire • 10/24/24
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024GlobeNewsWire • 10/22/24
Biogen's stock bounces after FDA boost on kidney-transplant rejection treatmentMarket Watch • 10/09/24
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant RecipientsGlobeNewsWire • 10/09/24
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMAGlobeNewsWire • 10/08/24
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatmentMarket Watch • 09/24/24